A study published in Nature highlights the potential of donor-derived cell-free DNA (dd-cfDNA) as a non-invasive biomarker for detecting kidney allograft rejection. The research, involving 2,882 kidney transplant recipients from 14 centers in Europe and the US, found that dd-cfDNA levels strongly correlate with rejection, including antibody-mediated rejection (AMR), T cell-mediated rejection (TCMR), and mixed rejection. In multivariable analysis, dd-cfDNA was significantly associated with rejection (OR 2.275; 95% CI 1.902–2.739; P < 0.0001), independent of standard monitoring parameters. Adding dd-cfDNA to standard models improved discrimination (AUC 0.821) and calibration. These results were validated in external cohorts, including African American patients. dd-cfDNA showed high predictive value for subclinical rejection. The study demonstrates that dd-cfDNA can enhance the detection of allograft rejection beyond standard monitoring, offering a non-invasive, cost-effective alternative to biopsies. The findings suggest that integrating dd-cfDNA into clinical practice could improve early diagnosis and management of rejection, reducing the need for invasive biopsies and improving patient outcomes. The study also highlights the need for further research to confirm the clinical utility of dd-cfDNA in diverse populations.A study published in Nature highlights the potential of donor-derived cell-free DNA (dd-cfDNA) as a non-invasive biomarker for detecting kidney allograft rejection. The research, involving 2,882 kidney transplant recipients from 14 centers in Europe and the US, found that dd-cfDNA levels strongly correlate with rejection, including antibody-mediated rejection (AMR), T cell-mediated rejection (TCMR), and mixed rejection. In multivariable analysis, dd-cfDNA was significantly associated with rejection (OR 2.275; 95% CI 1.902–2.739; P < 0.0001), independent of standard monitoring parameters. Adding dd-cfDNA to standard models improved discrimination (AUC 0.821) and calibration. These results were validated in external cohorts, including African American patients. dd-cfDNA showed high predictive value for subclinical rejection. The study demonstrates that dd-cfDNA can enhance the detection of allograft rejection beyond standard monitoring, offering a non-invasive, cost-effective alternative to biopsies. The findings suggest that integrating dd-cfDNA into clinical practice could improve early diagnosis and management of rejection, reducing the need for invasive biopsies and improving patient outcomes. The study also highlights the need for further research to confirm the clinical utility of dd-cfDNA in diverse populations.